Results 161 to 170 of about 2,988 (212)
Some of the next articles are maybe not open access.
The pharmacokinetic profile of pirenzepine.
Scandinavian journal of gastroenterology. Supplement, 1980This paper gives a brief review of the pharmacokinetic studies performed on pirenzepine (L S 519 Cl2, Gastrozepin hitherto. Particular attention will be paid thereby to the clinical significance of the pharmacokinetic parameters.
R, Hammer, F W, Koss
openaire +1 more source
What are the indications of pirenzepine?
1989At the parietal gastric cells where hydrochloric acid is secreted there are cholinergic receptors, particularly muscarinic receptors. Pirenzepine is a pyridobenzodiazepine which blocks the Ml muscarinic receptors of the gastric wall exerting a selective anti- muscarinic action.
openaire +1 more source
Central action of pirenzepine.
Polish journal of pharmacology and pharmacy, 1982Pirenzepine, (5,11-dihydro-11-[(4-methylpiperazin-1-yl)-acetyl]-6H-pyrido-[2,3] [1,4]-benzodiazepin-6-one dihydrochloride), tested on rats and mice, did not demonstrate any conspicuous behavioral action: it did not counteract reserpine hypothermia in mice, the L-DOPA hypermotility of mice, and (with the exception of very large doses) the amphetamine ...
Z, Rogóz, G, Skuza, H, Sowińska
openaire +1 more source
Psychometric studies of pirenzepine.
Scandinavian journal of gastroenterology. Supplement, 1981A single dose of 10 mg of pirenzepine given i.m. to 7 healthy volunteers did not elicit local or general signs of intolerance within 6 hours after injection. We also found no significant differences in tests of vegetative symptomatology, visual motor coordination, attention concentration, critical flicker test threshold, nor any other aspects of the ...
E, Kuhn, R, Honzák
openaire +1 more source
[The bronchodilating effect of pirenzepine].
Arerugi = [Allergy], 1992The purpose of this study was to clarify the bronchodilating effect of pirenzepine (PZ) and to verify its mechanism. Ten asthmatic patients (6 men, 4 women: aged 20 to 65, 5 atopic 5 non-atopic) and ten non-asthmatic volunteers (8 men, 2 women: aged 25 to 60) were studied. Forced vital capacity (FVC), forced expiratory volume in one second (FEV1.0) and
T, Shioya +5 more
openaire +1 more source
Pirenzepine in the treatment of duodenal ulcer.
Scandinavian journal of gastroenterology. Supplement, 1980The effectiveness and safety of pirenzepine (PRZ) at 150 mg daily in the treatment of active duodenal ulcer was studied in an open pilot clinical trial followed by a double-blind trial against placebo. The open pilot study showed that pirenzepine was well tolerated and promoted ulcer healing in the 45% of patients within 2 weeks of treatment and in 90%
N, D'Imperio +4 more
openaire +1 more source
Pirenzepine for clozapine-induced hypersalivation
The Lancet, 1995J, Fritze, T, Elliger
openaire +2 more sources
The effect of pirenzepine on esophageal motility.
Scandinavian journal of gastroenterology. Supplement, 1982The effect of pirenzepine on esophageal motility was studied in ten healthy volunteers by manometry. Pirenzepine reduces lower esophageal sphincter pressure (LESP), amplitude, and duration of esophageal contractions, but it increases velocity of propagation of esophageal contractions.
E, Erckenbrecht +4 more
openaire +1 more source
Acute effects of pirenzepin on bronchospasm.
International journal of clinical pharmacology, therapy, and toxicology, 1987The response to pirenzepin, a new acetylcholine receptor blocking agent, was assessed and compared to placebo in patients with reversible bronchoconstriction. A single intravenous injection of 20 mg of pirenzepin induced a significant reduction of airway resistance compared to placebo (p less than 0.05). The anticholinergic substance pirenzepin appears
K, Sertl +5 more
openaire +1 more source